BioNTech SE reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was EUR 187.6 million compared to EUR 1,277 million a year ago. Net loss was EUR 315.1 million compared to net income of EUR 502.2 million a year ago.

Basic loss per share from continuing operations was EUR 1.31 compared to basic earnings per share from continuing operations of EUR 2.07 a year ago. Diluted loss per share from continuing operations was EUR 1.31 compared to diluted earnings per share from continuing operations of EUR 2.05 a year ago.